Follow the Cash: When Raised Capital Doesn't Move

 In April and May 2026, Korean biotech companies collectively issued more than 1.1 trillion won — approximately $807 million — in zero-coupon convertible bonds. The structure is simple: no interest, no maturity coupon, just a bet on share-price upside embedded in the conversion option. D&D Pharmatec alone raised 226.5 billion won ($166 million) in a single deal, the largest CB transaction in the Korean biotech sector this year (Seoul Economic Daily, 2026.05.03).

For issuing companies, the logic is compelling. Capital arrives with no cash-outflow burden. The balance sheet swells. Optically, the company looks well-funded.

But the question that matters to individual investors is not how much was raised. It's where the money went.

The CGI Signal

RaymondsIndex tracks this question through the Cash Governance Index (CGI) — one of four leading indicators that measure the structural health of a company's relationship with its own capital. CGI specifically monitors three patterns: the idle cash ratio, the short-term financial instrument ratio, and the conversion rate of raised funds into deployed capital.

When a company raises a large sum and parks it in short-term financial instruments — bank deposits, money market products, short-duration bonds — the CGI score declines. Not because holding cash is inherently wrong, but because it signals a structural disconnect between the fundraising narrative and actual capital deployment.

The pattern is not unique to biotechs. Across the 3,109 Korean listed companies tracked by RaymondsIndex, 78% of firms that fell into the low-CGI category showed measurable deterioration in reinvestment metrics within 18 months of the initial signal.

The Structural Problem with Zero-Rate CB Markets

Zero-coupon CBs create a particular governance blind spot. Because there is no interest obligation, the company faces no near-term cash pressure to deploy the funds. This removes one of the natural forcing functions that would otherwise compel a management team to make deployment decisions on a timeline.

The result is a form of what economists call the free cash flow problem — a term introduced by Michael Jensen in his foundational 1986 paper in the American Economic Review. Jensen argued that when managers control large pools of cash beyond what is needed for positive-NPV projects, the probability of value-destroying decisions — empire-building, asset entrenchment, or simple inaction — rises significantly (Jensen, 1986).

Decades later, Dittmar and Mahrt-Smith (2007) extended this insight to show that governance quality directly determines the value that markets place on cash holdings. In poorly governed firms, an extra dollar of cash was valued by the market at significantly less than face value — sometimes as low as $0.42 to $0.88 per dollar held — because investors anticipate its misuse or immobilization (Dittmar & Mahrt-Smith, 2007, Journal of Financial Economics).

The Korean biotech CB wave of 2026 sits squarely in this analytical frame.

What Individual Investors Should Watch

The governance gap in Korean markets is structural. Information about where raised capital actually flows — whether into R&D budgets, CAPEX, overseas investment, or short-term instruments — is disclosed through filings, but rarely synthesized in a way that connects capital movements to governance risk.

RaymondsIndex was built precisely to close this gap. By tracking CGI alongside CEI (Capital Efficiency Index), RII (Reinvestment Intensity Index), and MAI (Momentum Alignment Index), the system produces a composite relational risk score (RRS) that reflects not just what a company reports, but what its capital behavior suggests about the priorities of those controlling it.

The financial statements will eventually catch up. The CGI signal moves first.

When a company raises 1.1 trillion won at zero interest and the stated rationale includes phrases like "preemptive response to uncertain market environment" — that is precisely the moment to start watching where the cash goes.

→ konnect-ai.net